<DOC>
	<DOCNO>NCT00001953</DOCNO>
	<brief_summary>This study aim learn immune hormonal system function patient Sjogren 's syndrome , disease immune system function properly . Adult nonpregnant female invite participate . Oral contraceptive may take 6 week study , another form birth control must use , abstinence . There two visit . At first visit , medical history physical examination conduct , blood urine test do . The total amount blood drawn 10 tablespoon . This visit last 3 hour . At second visit , participant oral glucose tolerance test . To prepare , must special diet 3 day beforehand keep diary eating , sleeping , physical activity 3 day . A urine sample take begin visit . Subjects must drink sweet carbonated cola . A small plastic tube place arm vein . Blood drawn tube eight time 3 hour . The total amount blood drawn 17 tablespoon . Only minor inconvenience anticipate result participate study . Risks blood test include soreness , bruising , minor infection puncture site , dizziness . The oral glucose tolerance test may cause temporary stomach bloating , headache , nausea , vomit .</brief_summary>
	<brief_title>The Functioning Immune Hormonal Systems Patients With Sjogren 's Syndrome Healthy Volunteers</brief_title>
	<detailed_description>Sjogren 's syndrome chronic systemic disease primarily affect salivary lacrimal gland characterize lymphocytic tissue infiltration auto-antibody production . The pathogenesis Sjogren 's syndrome unknown . We hypothesize reduced somatostatin activity important factor promote immune dysregulation patient affect Sjogren 's syndrome . Somatostatin multifunctional peptide potent immunomodulatory property whose effect reduce lymphocytic activity , reduce gastrointestinal secretion , activation hypothalamic-pituitary axis , anti-inflammatory , etc . As several finding Sjogren 's syndrome opposite produce somatostatin , logical consider activity peptide low patient affected disease . The purpose study determine whether basal stimulate plasma level somatostatin effect immune endocrine system differ 16 patient affected primary Sjogren 's syndrome 16 healthy control subject .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Female gender , age 18 75 . Patients document primary Sjogren 's syndrome determine protocol 84D0056 . The diagnosis primary Sjogren 's syndrome base presence three follow : Salivary gland abnormality ; Lacrimal gland abnormality ; Serologic abnormality . Controls sign symptoms Sjogren 's syndrome , negative serologic test reconfirm within 2 week OGTT . Willingness : ) participate phase I II protocol ; b ) follow guideline set prepare OGTT ; c ) modify current medical therapy necessary . Must able comply protocol procedure . No patient `` incomplete '' Sjogren 's syndrome , i.e. , less three positive finding describe . No presence physical mental condition may interfere protocol . These include follow disease condition : ( Present time phase I/II ) : significant disruption sleepwake pattern ( i.e. , less 4 hour continuous sleep , night OGTT ) , BMI le 18 equal to/greater 30 , anemia Hgb le 10 gm/dl , use tobacco alcohol ; ( Within past 6 week ) : acute weight change ( great 5 % ) , use contraceptive BCP , Depoprovera Norplant ) , irregular menstrual cycle , lactation , blood draw excess 50 ml , use recreational drug , modification estrogen replacement therapy ; ( Within past 6 month ) : chronic pattern weight change ( great 10 % ) , eat disorder , uncontrolled hypo/hyperthyroidism , breast cancer , lymphoma malignancy , pregnancy , treatment depression , insulinoma , VIPoma , pheochromocytoma , atrophic gastritis , active tuberculosis treatment ; ( A history ) : HIV+ , sarcoidosis , secondary Sjogren 's syndrome , bleed diathesis , organ transplant , severe neuroendocrine , renal , cardiovascular , pulmonary gastrointestinal disease ( e.g. , renal insufficiency , unstable angina , heart failure , severe emphysema , Crohn 's disease ) , diabetes mellitus , acromegaly mental retardation . No contraindication OGTT . These include : Hospital inpatient status , acute illness , immobilization , starvation , severe emotional distress within one week OGTT ; Low carbohydrate diet ( le 150 g/day ) 3 day precede OGTT ; Pregnancy ; Therapy impair glucose tolerance : e.g. , niacin , thiazide diuretic , phenytoin , excess thyroxine psychotropic drug within 1 month phase I , oral contraceptive within 6 week phase I , glucocorticoid treatment within past 6 month ( one year treatment last 2 week ) , Beta blockers/agonists ( e.g. , terbutaline ) within 2 day phase I ; Diabetes mellitus ; Glucose intolerance . Subjects may take medication affect somatostatin level , antidepressant , benzodiazepine , neuromodulators ( e.g. , cholinergic , alpha/beta adrenergic ) , oral contraceptive ( BCP ) , steroid hormone ( exception estrogen replacement therapy ERT , subject match ) , immunomodulators , anticonvulsant ( e.g. , carbamazepine ) , cimetidine Tagamet® ( Registered Trademark ) , herbal remedy ( variable substance content ) . Subjects may take drug affect gastrin secretion : antacid ( e.g. , Maalox® ( Registered Trademark ) , Mylanta® ( Registered Trademark ) , H ( 2 ) receptor antagonist ( e.g. , famotidine Pepcid® ( Registered Trademark ) , ranitidine Zantac® ( Registered Trademark ) ) , cathecolamines , atropine , haloperidol . To become eligible , subject able safely discontinue medication least one month prior phase I. Antacids , H ( 2 ) antagonist neuromodulators ( e.g. , Salagen ) may discontinue 2 day prior phase I . Patients take experimental drug within 1 month begin protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Endocrine System</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Salivary Glands</keyword>
	<keyword>Glucose Tolerance Test</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Somatostatin</keyword>
	<keyword>Sjogren 's Syndrome</keyword>
</DOC>